Last reviewed · How we verify
Sequence 4
At a glance
| Generic name | Sequence 4 |
|---|---|
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP) (PHASE2)
- The Effect of NP-2006 on Sleep Quality and Health (NA)
- Pharmacokinetic and Subjective Effects of Heated Tobacco Products (NA)
- An Open-label, Randomized, Single-dose, Two-treatment, Four-period, Fully Replicate Crossover Bioequivalence Study in Healthy Female Adult Participants Under Fasting Conditions Comparing the Test Product, Prontogest Solution for IM Injection With the Reference Product, Progesterone Injection (PHASE1)
- Effectiveness of Mindful Attention Awareness Breathing on Attention and Wellbeing Among Undergraduate Students (NA)
- Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine (PHASE3)
- Combination Study of SV-BR-1-GM With Retifanlimab (PHASE1, PHASE2)
- A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sequence 4 CI brief — competitive landscape report
- Sequence 4 updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI